Table 3.
Multivariable regression results of the risk factors of nondisease-related mortality in 1- and 5-year survivors*
| Covariables | 1-year survivors | 5-year survivors | ||
|---|---|---|---|---|
| (n = 2956) | (n = 1725) | |||
| No. NDR deaths (n = 555) |
No. NDR deaths (n = 234) |
|||
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex | ||||
| Female | 1.0 (Referent) | 1.0 (Referent) | ||
| Male | 1.31 (1.10 to 1.56) | .002 | 1.39 (1.06 to 1.82) | .02 |
| Age at alloHCT, y | ||||
| As continuous variable | 1.03 (1.02 to 1.04) | <.001 | 1.06 (1.04 to 1.07) | <.001 |
| As categorical variable | <.001† | <.001† | ||
| <40 | 1.0 (Referent) | 1.0 (Referent) | ||
| 40–60 | 1.78 (1.44 to 2.21) | <.001 | 2.78 (1.99 to 3.89) | <.001 |
| >60 | 2.33 (1.63 to 3.32) | <.001 | 5.39 (2.77 to 10.47) | <.001 |
| Race/ethnicity | .08† | .11† | ||
| Non-Hispanic white | 1.0 (Referent) | 1.0 (Referent) | ||
| Hispanic | 1.16 (0.96 to 1.41) | .13 | 0.93 (0.70 to 1.25) | .64 |
| Asian | 0.79 (0.57 to 1.10) | .16 | 0.57 (0.34 to 0.97) | .04 |
| African American, other race, missing | 1.30 (0.87 to 1.92) | .20 | 1.44 (0.76 to 2.74) | .27 |
| Primary diagnosis | .10† | .03† | ||
| ALL | 1.0 (Referent) | 1.0 (Referent) | ||
| AML, MDS | 0.82 (0.65 to 1.03) | .09 | 0.82 (0.57 to 1.18) | .29 |
| CML | 0.68 (0.53 to 0.88) | .003 | 0.55 (0.38 to 0.80) | .002 |
| NHL, HL | 0.76 (0.54 to 1.06) | .10 | 0.74 (0.42 to 1.29) | .29 |
| CLL, MM, other leukemia | 0.76 (0.45 to 1.29) | .31 | 0.42 (0.18 to 0.99) | .047 |
| SAA, other hematologic diseases | 0.79 (0.48 to 1.32) | .37 | 0.79 (0.34 to 1.83) | .58 |
| Donor type | ||||
| Related | 1.0 (Referent) | 1.0 (Referent) | ||
| Unrelated | 1.38 (1.12 to 1.71) | .002 | 1.35 (0.94 to 1.95) | .10 |
| Relapse risk at alloHCT | ||||
| Standard risk | 1.0 (Referent) | 1.0 (Referent) | ||
| High risk | 1.16 (0.97 to 1.40) | .11 | 1.28 (0.95 to 1.71) | .10 |
| GvHD within 1 y of alloHCT | ||||
| No | 1.0 (Referent) | 1.0 (Referent) | ||
| Yes | 1.86 (1.49 to 2.32) | <.001 | 1.33 (1.00 to 1.78) | 0.05 |
| Total body irradiation | ||||
| Unexposed | 1.0 (Referent) | 1.0 (Referent) | ||
| Exposed | 1.35 (1.08 to 1.70) | .01 | 1.77 (1.18 to 2.64) | .006 |
| Year of alloHCT | ||||
| As continuous variable | 0.95 (0.94 to 0.96) | <.001 | 0.95 (0.93 to 0.97) | <0.001 |
| As categorical variable | <.001† | <.001† | ||
| 1976–1989 | 1.0 (Referent) | 1.0 (Referent) | ||
| 1990–1994 | 0.70 (0.53 to 0.94) | .02 | 0.66 (0.46 to 0.97) | .03 |
| 1995–1999 | 0.61 (0.46 to 0.82) | <.001 | 0.53 (0.35 to 0.80) | .003 |
| 2000–2004 | 0.42 (0.31 to 0.57) | <.001 | 0.45 (0.29 to 0.71) | <.001 |
| 2005–2009 | 0.32 (0.23 to 0.45) | <.001 | 0.33 (0.19 to 0.57) | <.001 |
| 2010–2014 | 0.26 (0.18 to 0.37) | <.001 | 0.26 (0.09 to 0.80) | .02 |
Sex, age at alloHCT, race and/or ethnicity, primary diagnosis, relapse risk, and year of alloHCT were included in the model regardless of statistical significance. ALL = acute lymphocytic leukemia; alloHCT = allogeneic hematopoietic cell transplantation; AML = acute myeloid leukemia; CI = confidence interval; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; GvHD = graft-versus-host disease; HL = Hodgkin lymphoma; HR = hazard ratio; MDS = myelodysplastic syndromes; MM = multiple myeloma; NHL = non-Hodgkin lymphoma; NDR = nondisease-related; SAA = severe aplastic anemia.
P value for test of homogeneity of categorical variables.